Comparing the Efficacy of Double Dose Hepatitis B Vaccine with Conventional Dose Hepatitis B Vaccine in CLD Patients

2021 ◽  
Vol 15 (8) ◽  
pp. 1861-1863
Author(s):  
Mohammad Hamid ◽  
Tahir Ullah Khan ◽  
Atif Masood ◽  
Faisal Amin Baig ◽  
Wali Khan ◽  
...  

Aim: To compare the efficacy of double dose hepatitis B vaccine with conventional dose hepatitis B vaccine in hepatitis C related chronic liver disease patients. Study design: Interventional study (randomized controlled clinical trial) Place and duration of study: Outpatient Department of Medicine, Services Hospital, Lahore from 12th August 2019 to 12th February 2020. Methodology: One hundred and ten patients of both male and female age group 30 to 70 years diagnosed with chronic liver disease on the basis of changed liver echo texture on ultrasound were included. Patients were divided into two groups, each group having 55 patients. One group was given double dose (2ml) while the other was given conventional dose (1ml). Both groups were compared for efficacy in terms of prevention of CLD. Results: The mean age of conventional group was 33.8±9.6 years while 33.7±9.1 years in the double dose group with male predominance (69.10%). Hypo-responsiveness was detected in 23.6% and 32.7% of conventional low dose group and double dose group respectively. There were gender variations in mean Anti-HBs levels. It was 129.80±70.53 mIU/mL in males and 113.26±75.57 mIU/mL in female patients (P= 0.039). Mean titers of anti-HBs in conventional dose group and high dose group were 127.82±67.59 mIU/mL and 121.56±77.00 mIU/mL, respectively (P= 0.52). Conclusion: Double dose hepatitis B vaccination in chronic HCV infected patients efficiently increases the response rate and hence protection against chronic hepatitis B. Keywords: Double dose hepatitis B vaccine, conventional hepatitis B vaccine, chronic hepatitis.

2002 ◽  
Vol 36 ◽  
pp. 229
Author(s):  
Cristiane Both ◽  
Eliana Gomes ◽  
Claudio Alexandre ◽  
Jose Remiao ◽  
Gabriela Coral ◽  
...  

2006 ◽  
Vol 13 (4) ◽  
pp. 217-221 ◽  
Author(s):  
A. Aziz ◽  
S. Aziz ◽  
D. S. Li ◽  
L. Murphy ◽  
N. Leone ◽  
...  

Blood ◽  
2015 ◽  
Vol 126 (23) ◽  
pp. 5567-5567 ◽  
Author(s):  
Mashrafi Ahmed ◽  
Fawwad Zaidi ◽  
Tahmina Begum ◽  
Ashok R. Patel

Abstract Introduction: Cirrhosis of liver due to chronic hepatitis B and/or C is a significant health care burden globally. Thrombocytopenia is one of the significant co-morbid conditions associated with cirrhosis. Splenomegaly had been pointed as one of the main factors behind thrombocytopenia in multiple studies. Another important aspect of this clinical condition is its high economic impact in the national health care budget. In this study, we re-evaluated the relation between thrombocytopenia, MELD score and spleen size in liver cirrhosis associated with chronic hepatitis B and/or C. We also evaluated the impact of these 3 factors over readmission of the patients at 30 and 90 days. Method: In this retrospective study, the medical records of patients admitted to Saint Joseph Hospital, Chicago, IL between January 1st, 2005 and December 31st, 2010 were queried for a discharge diagnosis of Chronic liver disease due to Hepatitis B and/or C. Result: Data Summary To examine the relationship between the biomarkers, scatter plot was generated for visual inspection. There was no apparent relationship between platelet count and MELD or spleen size. Correlation analysis by Spearman method showed a weak negative correlation between platelet count and MELD score (P=0.0051, coefficient = -0.26). To predict the probability of re-admission by the biomarkers, logistic regression was used to select significant predictors. From univariate analysis, only MELD was a significant predictor in 30-day re-admission (P=0.012, AUC=0.665). For 90-day re-admission, both MELD (P=0.0034, AUC=0.691) and platelet count (P=0.030, AUC=0.647) were significant predictors in univariate analysis. Summary In this study, all subjects have chronic liver disease due to viral infection. Platelet count is not related to MELD score or spleen size in these hepatitis B, C, or B/C patients. The combination of MELD, platelet count, and spleen size fairly predicts 30-day re-admission occurrence with an AUC of 0.726. Discussion: Thrombocytopenia is a common hematological complication in patient with chronic liver disease. The mechanism of thrombocytopenia classically is thought to be caused by pooling and destruction of platelets within the enlarged spleen. Other proposed mechanisms are impaired platelet production in the bone marrow, production of inhibitors of platelet production in the spleen, and decreased platelet growth factor thrombopoietin production from liver as well as increased degradation of thrombopoietin by platelets sequestered in the congested spleen. A recent study showed that in more severe chronic hepatitis due to hepatitis-c virus where severity was assessed with Child-Pugh score, both mature and premature platelet counts are low and this inverse relation also correlates with platelet growth factor thrombopoietin level which is low in more severe liver disease. Since Child-Pugh scoring system has some degree of limitation due to subjective variation, we decided to use MELD score for our patients to assess the severity of the chronic liver disease. Our study interestingly showed no correlation between platelet count, MELD score and spleen size. Study revealed only MELD was a significant predictor in 30-day re-admission (P=0.012, AUC=0.665). For 90-day re-admission, both MELD (P=0.0034, AUC=0.691) and platelet count (P=0.030, AUC=0.647) No correlation was observed even when cohorts were broken down into separately for male and female, for patients below and above 62 years old (the median age), and for each hepatitis subtype. 30-day re admission was clearly not related Platelet count or spleen alone but in combination they were linearly related to 30 and 90 day readmission. This study was important for multiple reasons. Firstly, 30 day readmission was calculated to be 16% and 90 day readmission was found to be 29% including the 16% from 30-day readmission. Surprisingly MELD alone was not a good predictor for 30 day readmission, but in combination with other parameters Spleen size and platelet count, predictions were fairly accurate. Table 1. Statistical Analysis and Results Table 1. Statistical Analysis and Results Figure 1. ROC of 30-day re-admission. Figure 1. ROC of 30-day re-admission. Figure 2. ROC of 90-day re-admission. Figure 2. ROC of 90-day re-admission. Disclosures No relevant conflicts of interest to declare.


Gut ◽  
1998 ◽  
Vol 42 (1) ◽  
pp. 107-111 ◽  
Author(s):  
M Guilera ◽  
J C Sáiz ◽  
F X López-Labrador ◽  
E Olmedo ◽  
S Ampurdanés ◽  
...  

Background—The hepatitis G virus (HGV), a recently identified member of the Flaviviridae family, can cause chronic infection in man but the role of this agent in chronic liver disease is poorly understood.Aims—To evaluate the prevalence and meaning of HGV infection in a large series of patients with chronic liver disease.Subjects—Two hundred volunteer blood donors, 179 patients with chronic hepatitis C, 111 with chronic hepatitis B, 104 with alcoholic liver disease, 136 with hepatocellular carcinoma, and 24 with cryptogenic chronic liver disease were studied.Methods—HGV RNA was investigated in serum samples by reverse transcription and polymerase chain reaction amplification of the 5′ non-coding region of HCV and hybridisation to a specific probe. The main features of HGV RNA seropositive and seronegative patients were compared.Results—The prevalence of HGV infection was 3% in blood donors, 7% in chronic hepatitis C, 8% in chronic hepatitis B, 2% in alcoholic liver disease, 4% in hepatocellular carcinoma, and 8% in cryptogenic chronic liver disease. HGV infected patients tended to be younger than non-infected patients but no differences concerning sex, possible source of infection, clinical manifestations, biochemical and virological parameters, or severity of liver lesions were found.Conclusions—The prevalence of HGV infection in chronic liver disease seems to be relatively low in our area. Infection with HGV does not seem to play a significant pathogenic role in patients with chronic liver disease related to chronic HBV or HCV infection or to increased alcohol consumption, or in those with cryptogenic chronic liver disease.


Sign in / Sign up

Export Citation Format

Share Document